Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

Journal of Neurophysiology

Volumn 99, Issue 4, 2008, Pages 1590-1595

  Gault, Victor A ^a   Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE AGONIST; PEPTIDE HORMONE; PROLINE; PROTEINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE HOMEOSTASIS; HIPPOCAMPUS; HUMAN; INSULIN RELEASE; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE;

AMYLOID BETA-PROTEIN; ANIMALS; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; GASTRIC INHIBITORY POLYPEPTIDE; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; LONG-TERM POTENTIATION; MALE; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; RATS; RATS, WISTAR; SYNAPSES;

EID: 42249106405     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.01161.2007     Document Type: Article

References (39)

1. 2+-dependent late phase. J Neurochem 67: 2074-2078, 1996.
2. Arias C, Arrieta I, Tapia R. beta-Amyloid peptide fragment 25-35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. J Neurosci Res 41: 561-566, 1995.
3. Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 77: 304-307, 2006.
4. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in T2DM: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33: 1041-1044, 2005.
5. Carro E, Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490: 127-133, 2004.
6. Freir DB, Herron CE. Inhibition of L-type voltage dependent calcium channels causes impairment of long-term potentiation in the hippocampal CA1 region in vivo. Brain Res 967: 27-36, 2003.
7. Freir DB, Hölscher C, Herron CE. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol 85: 708-713, 2001.
8. Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'Harte FP, Flatt PR. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54: 2436-2446, 2005.
9. Gengler S, Gault VA, Harriott P, Hölscher C. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp Brain Res 179:621-630, 2007.
10. Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 87: 1137-1144, 2003.
11. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23: 542-549, 2000.
12. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/ Ala2 with 2-aminobutyric acid. Arch Biochem Biophys 428: 136-143, 2004.
13. +-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem 67: 277-286, 1996.
14. Hölscher C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 5: 129-141, 1998.
15. Hölscher C. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev Neurosci 16: 181-212, 2005.
16. Hölscher C, Gengler S, Gault V, Harriott P, Mallot H. Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 561: 85-90, 2007.
17. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490: 115-125, 2004.
18. Irwin N, Green BD, Gault VA, Harriot P, O'Harte FP, Flatt PR. Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Exp Gerontol 41: 151-156, 2006.
19. Irwin N, Green BD, Mooney MH, Greer B, Harriott P, Bailey CJ, Gault VA, O'Harte FP, Flatt PR. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther 314: 1187-1194, 2005.
20. - channel activity in rat cortical astrocytes. Brain Res 746: 85-97, 1997.
21. Janson J, Laedtke T, Parisi J, O'Brien P, Petersen R, Butler P. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481, 2004.
22. Leech C, Habener J. Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin. J Biol Chem 272: 17987-17993, 1997.
23. Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56: 384-402, 2007.
24. Nyberg J, Anderson MF, Meister B, Alborn AM, Strom AK, Brederlau A, Illerskog AC, Nilsson O, Kieffer TJ, Hietala MA, Ricksten A, Eriksson PS. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 25: 1816-1825, 2005.
25. Nyberg J, Jacobsson C, Anderson MF, Eriksson PS. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res 85: 2099-2119, 2007.
26. Okamoto N, Hore S, Akazawa C, Hayashi Y, Shigemoto R, Mizuno N, Nakanishi S. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J Biol Chem 269: 1231-1236, 1994.
27. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53: 1937-1942, 1999.
28. + channels during neuronal apoptosis (Abstract). Proceedings of the 4th Forum of the Federation of European Neurosciences, Lisbon, Portugal, 2004, A159.121.
29. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2: 377-385, 2005.
30. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72: 603-612, 2003.
31. Steen E, Terry BM, Rivera E, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7: 63-80, 2005.
32. Stockhorst U, de Fries D, Steingrueber HJ, Scherbaum WA. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav 83: 47-54, 2004.
33. Strachan MW. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem Soc Trans 33: 1037-1040, 2005.
34. + channel subunit Kir6.2 in mouse pancreas. Diabetes 46: 1440-1444, 1997.
35. Trudeau F, Gagnon S, Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur J Pharmacol 490: 177-186, 2004.
36. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24: 3370-3378, 2004.
37. 2+ channels in supporting hippocampal synaptic transmission. Science 264: 107-111, 1994.
38. Winder DG, Conn PJ. Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. J Neurosci 13: 38-44, 1993.
39. Zhao W-Q, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22: 246-260, 2008.